CeriBell, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CeriBell, Inc. (CBLL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $11.40 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-10
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $13.31, a 3.27% decline year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $13.76, a 176.86% increase year-over-year.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.97.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $10.12, a 35.66% increase from fiscal 2024.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $7.46, a 131.68% increase from fiscal 2023.
- CeriBell, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.22.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.40 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $13.31 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $10.12 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $10.47 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $10.47 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $13.76 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $7.46 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $7.19 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $5.92 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $4.97 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $3.22 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |